Becker's Healthcare January 14, 2025
Alexandra Murphy

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company’s key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10.

The write down comes after emraclidine missed crucial goals in two mid-stage trials, prompting AbbVie to reassess the drug’s value. In November, the company revealed that the drug failed to meet...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025
How Technology is Impacting Launch Strategy Timelines
mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Community Pharmacists as Experts on Complex Patient Encounters

Share This Article